Articles from BioCryst Pharmaceuticals, Inc.

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—

By BioCryst Pharmaceuticals, Inc. · Via GlobeNewswire · June 29, 2026

Articles from BioCryst Pharmaceuticals, Inc. | FinancialContent